Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American …
Writing Committee Members, SR Ommen… - Journal of the American …, 2024 - jacc.org
Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Developed by the task force for the …
4004 ESC Guidelines label use of medication should be limited to situations where it is in
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …
the patient's interest to do so, with regard to the quality, safety, and efficacy of care, and only …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American …
The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …
initial extensive evidence review, which included literature derived from research involving …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …
provides recommendations and algorithms for clinicians to diagnose and manage …
JCS/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias
A Nogami, T Kurita, H Abe, K Ando, T Ishikawa… - Circulation …, 2021 - jstage.jst.go.jp
Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
coverage in Japan in 1974, and its use rapidly became widespread thereafter …
Vigorous exercise in patients with hypertrophic cardiomyopathy
R Lampert, MJ Ackerman, BS Marino, M Burg… - JAMA …, 2023 - jamanetwork.com
Importance Whether vigorous intensity exercise is associated with an increase in risk of
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown …
ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown …
2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of …
The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …
initial extensive evidence review, which included literature derived from research involving …
Clinical course and management of hypertrophic cardiomyopathy
BJ Maron - New England Journal of Medicine, 2018 - Mass Medical Soc
Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …
Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …